Advanced science (Weinheim, Baden-Wurttemberg, Germany)Jul 14, 2026

Improved lipid nanoparticles with modified fats for safer mRNA delivery

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jul 15, 2026

Abstract

A 56-member library of tail-modified ionizable lipids was synthesized to evaluate their delivery behavior in mRNA therapeutics.

Hydrophobic tail architecture is crucial for determining endosomal escape and biocompatibility.
Optimized lipid nanoparticles (LNPs) demonstrated significant improvements in mRNA translation efficiency.
The study identified that modified LNPs resulted in reduced cytotoxicity and lower cytokine induction.
Balanced Th1/Th2 immune activation was observed in a nonhuman primate model with the optimized LNPs.
A comprehensive structure-activity relationship framework was established, linking tail chemistry to lipid function.

Simplified

Despite the growing importance of lipid nanoparticles (LNPs) in mRNA therapeutics, current ionizable lipids, which comprise an ionizable head group, a linker, and hydrophobic tails that collectively govern the delivery behavior, exhibit dose-limiting toxicity and suboptimal efficiency. Hydrophobic tail chemistry has been implicated in these limitations; however, a systematic structure-activity relationship (SAR) analysis is lacking. In this study, the authors synthesized a 56-member library of tail-modified ionizable lipids with biodegradable disulfide linkages and variations in chain length and branching. Systematic SAR evaluation revealed that hydrophobic tail architecture critically determines endosomal escape, biocompatibility, and mRNA translation efficiency. Optimized LNPs delivered mRNA with potent efficacy and markedly reduced cytotoxicity, lower cytokine induction, and balanced Th1/Th2 immune activation in a nonhuman primate model. The findings establish the first comprehensive SAR framework linking tail chemistry to ionizable lipid function, offering molecular design principles for next-generation LNPs and enabling the development of safer and more effective mRNA-based vaccines and therapeutics.